New combo therapy aims to delay prostate cancer relapse in patients with limited spread
NCT ID NCT02274779
First seen Feb 17, 2026 · Last updated Jun 20, 2026 · Updated 19 times
Summary
This study tested a combination of high-dose radiation and hormone therapy (leuprorelin) in 74 men with prostate cancer that had returned in up to 5 pelvic lymph nodes after initial treatment. The goal was to see if this approach could delay further cancer growth or relapse. Participants received radiation to the affected nodes plus six months of hormone therapy, and researchers tracked how long it took for the cancer to progress again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ICO Paul Papin
Angers, France
-
ICO René Gauducheau
Saint-Herblain, 44800, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Leuprorelin (Eligard) hormone therapy plus high-dose radiation therapy
What this could lead to
If successful, this combination could delay the return of prostate cancer after initial treatment, potentially extending the time before more aggressive therapy is needed.
What could go wrong
This is a small, early-phase trial (74 participants) with no control group, so results may not apply broadly. Hormone therapy has side effects like hot flashes and fatigue, and the treatment may not prevent eventual relapse.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.